Pacira BioSciences Mails Letter to Stockholders
Pacira BioSciences reported first quarter 2026 revenue of $177 million, up 5% year-over-year and exceeding consensus estimates, driven by strong performance across its product portfolio. The company generated $40.2 million in Adjusted EBITDA and ended the quarter with $202 million in cash and investments, having repurchased $50 million of stock in the period.
Key figures
- Revenue
- 177000000
- Revenue Yoy
- 5%
- Shares retired
- 2200000
- Adjusted ebitda
- 40200000
- Iovera q1 sales
- 6200000
- Exparel q1 sales
- 143300000
- Zilretta q1 sales
- 26800000
- Total revenues 2025
- 726400000
- Cash and investments
- 202000000
- Share repurchase amount
- 50000000
- Non gaap gross margin 2025
- 81.2%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.